CA3218345A1 - Agonistes macrocycliques du recepteur du peptide 1 de type glucagon - Google Patents

Agonistes macrocycliques du recepteur du peptide 1 de type glucagon Download PDF

Info

Publication number
CA3218345A1
CA3218345A1 CA3218345A CA3218345A CA3218345A1 CA 3218345 A1 CA3218345 A1 CA 3218345A1 CA 3218345 A CA3218345 A CA 3218345A CA 3218345 A CA3218345 A CA 3218345A CA 3218345 A1 CA3218345 A1 CA 3218345A1
Authority
CA
Canada
Prior art keywords
preparation
mmol
methyl
title compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218345A
Other languages
English (en)
Inventor
Francisco Javier Agejas Chicharro
Renato Alejandro BAUER
Michael Gregory Bell
Qi Chen
Graham Robert Cumming
Todd Fields
Douglas Linn Gernert
Joseph Daniel HO
Talbi Abelkader KAOUDI
Thierry Jean MASQUELIN
Jose Miguel Minguez Ortega
Julian PRIEGO SOLER
Antonio Rodriguez Hergueta
Eric Michael Woerly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3218345A1 publication Critical patent/CA3218345A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dans un mode de réalisation, la présente invention concerne un composé de formule : ou un sel pharmaceutiquement acceptable de celui-ci, et des méthodes d'utilisation de ce composé pour le traitement du diabète sucré de type II.
CA3218345A 2021-05-20 2022-05-19 Agonistes macrocycliques du recepteur du peptide 1 de type glucagon Pending CA3218345A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163191034P 2021-05-20 2021-05-20
US63/191,034 2021-05-20
US202163254564P 2021-10-12 2021-10-12
US63/254,564 2021-10-12
EP21383172 2021-12-21
EP21383172.0 2021-12-21
PCT/US2022/029958 WO2022246019A1 (fr) 2021-05-20 2022-05-19 Agonistes macrocycliques du récepteur du peptide 1 de type glucagon

Publications (1)

Publication Number Publication Date
CA3218345A1 true CA3218345A1 (fr) 2022-11-24

Family

ID=82016585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218345A Pending CA3218345A1 (fr) 2021-05-20 2022-05-19 Agonistes macrocycliques du recepteur du peptide 1 de type glucagon

Country Status (10)

Country Link
EP (1) EP4341255A1 (fr)
JP (1) JP7703691B2 (fr)
KR (1) KR20230173166A (fr)
AU (1) AU2022275931B2 (fr)
BR (1) BR112023022851A2 (fr)
CA (1) CA3218345A1 (fr)
IL (1) IL308397A (fr)
MX (1) MX2023013717A (fr)
TW (1) TWI843104B (fr)
WO (1) WO2022246019A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
EP4592285A1 (fr) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Composé à cycle condensé ayant un effet agoniste du récepteur glp-1
WO2024102625A1 (fr) * 2022-11-11 2024-05-16 Eli Lilly And Company Agonistes de récepteur du peptide 1 de type glucagon
EP4568664B1 (fr) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combinaison comprenant un agoniste thr-beta et un agoniste glp-1r pour son utilisation dans le traitement de l'obésité
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025158275A1 (fr) 2024-01-24 2025-07-31 Pfizer Inc. Polythérapie utilisant des composés antagonistes du récepteur du polypeptide insulinotrope glucose-dépendant et des composés agonistes du récepteur glp-1
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
CN119219759B (zh) * 2024-10-22 2026-03-27 浙江工业大学 一种双水相萃取耦合反相柱层析分离纯化发酵液中glp-1类似物的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102314286B1 (ko) * 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
DK3806855T5 (da) 2018-06-15 2023-05-22 Pfizer GLP-1-receptoragonister og anvendelser deraf
MA54555A (fr) 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
EP3953344A4 (fr) * 2019-04-12 2023-08-09 Qilu Regor Therapeutics Inc. Agonistes de glp-1r et leurs utilisations
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (fr) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 Modulateur du récepteur glp-1 à petites molécules
EP4048664A1 (fr) * 2019-10-25 2022-08-31 Gilead Sciences, Inc. Composés modulateurs de glp-1r
WO2021096284A1 (fr) 2019-11-15 2021-05-20 일동제약(주) Agoniste du récepteur glp-1 et son utilisation
CN114761395B (zh) 2019-12-02 2024-11-15 现代药品株式会社 Glp-1受体激动剂
ES3016132T3 (en) 2020-01-29 2025-05-08 Gilead Sciences Inc Glp-1r modulating compounds
JP7836762B2 (ja) 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
IL296336A (en) 2020-03-18 2022-11-01 Lg Chemical Ltd Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
MX2022015026A (es) 2020-06-04 2023-01-04 Hangzhou Sciwind Biosciences Co Ltd Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.
CN115697338B (zh) 2020-06-10 2024-08-09 东宝紫星(杭州)生物医药有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN113801136B (zh) 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN115916772B (zh) 2020-06-19 2025-01-14 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN113831337B (zh) 2020-06-24 2023-03-24 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
WO2022031994A1 (fr) 2020-08-06 2022-02-10 Qilu Regor Therapeutics Inc. Agonistes de glp-1r et leurs utilisations
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CA3192601A1 (fr) 2020-08-21 2022-02-24 Terns Pharmaceuticals, Inc. Composes en tant qu'agonistes de glp-1r
EP4204415A4 (fr) 2020-08-28 2025-03-26 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
CA3188891A1 (fr) 2020-09-01 2022-01-13 Fanglong Yang Derive d'imidazole condense, son procede de preparation et son utilisation medicale
WO2022068772A1 (fr) 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale
WO2022078152A1 (fr) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation
US20240083886A1 (en) 2020-10-13 2024-03-14 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4229050A4 (fr) 2020-10-13 2024-12-11 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用

Also Published As

Publication number Publication date
KR20230173166A (ko) 2023-12-26
WO2022246019A1 (fr) 2022-11-24
AU2022275931A1 (en) 2023-11-02
IL308397A (en) 2024-01-01
EP4341255A1 (fr) 2024-03-27
MX2023013717A (es) 2024-01-16
AU2022275931B2 (en) 2024-08-15
JP7703691B2 (ja) 2025-07-07
TW202310838A (zh) 2023-03-16
JP2024521073A (ja) 2024-05-28
BR112023022851A2 (pt) 2024-01-23
TWI843104B (zh) 2024-05-21

Similar Documents

Publication Publication Date Title
CA3218345A1 (fr) Agonistes macrocycliques du recepteur du peptide 1 de type glucagon
CA3144055C (fr) Agonistes du recepteur du peptide de type glucagon 1
AU2024227155A1 (en) Carboxy-benzimidazole GLP-1R modulating compounds.
EP2038272B1 (fr) Inhibiteurs de pyridinonyle pdk1
CN102665718B (zh) 可用作pdk1抑制剂的杂环化合物
US10017502B2 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
JP2017001991A (ja) 新規ベンズオキサゾロン化合物
AU2018257203B2 (en) Novel tetrahydronaphthyl urea derivatives
TWI843949B (zh) 黑皮質素4(melanocortin 4)受體拮抗劑及其用途
JP2025537254A (ja) グルカゴン様ペプチド１受容体アゴニスト
KR20250085816A (ko) 글루카곤-유사 펩티드 1 수용체 효능제
JP6797923B2 (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
CA2828518C (fr) Derives de pyridynyl- et pyrasinyl-methyloxy-aryl utiles comme inhibiteurs de tyrosine kinase spleniqueyk)
EP3807273B1 (fr) Dérivés d'azaindole comme inhibiteurs de la kinase rho
RU2662157C2 (ru) 2-пиридоновое соединение
US20240343740A1 (en) Macrocyclic glucagon-like peptide 1 receptor agonists
TW202613120A (zh) Gip受體促效劑化合物
CN117355517A (zh) 大环胰高血糖素样肽1受体激动剂
WO2025264700A1 (fr) Composés agonistes du récepteur gip
CA3288258A1 (fr) Nouvel inhibiteur de b0at1
WO2026030603A1 (fr) Composés agonistes du récepteur gip
WO2026026956A1 (fr) Composé inhibiteur de tacc, composition pharmaceutique, son procédé de préparation et son utilisation
EA048136B1 (ru) Спиросоединения в качестве антагонистов рецептора меланокортина 4 и их применения
HK1207856B (en) 2-pyridone compound
KR20110109917A (ko) 신규한 퀴녹살린 유도체

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231107

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241209

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250408

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250507

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260422